Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, Debus J, Peeken JC, Vogel ME, Vrachimis A, Spohn SKB, Shelan M, Aebersold D, Grosu AL, Ceci F, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Hruby G, Scharl S, Wiegel T, Bartenstein P, Henkenberens C, Emmett L, Schmidt-Hegemann NS, Ferentinos K, Zamboglou C. Solomonidou N, et al. Among authors: henkenberens c. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2529-2536. doi: 10.1007/s00259-023-06185-5. Epub 2023 Mar 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 36905411 Free PMC article.
Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.
Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T. Schmuck S, et al. Among authors: henkenberens c. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):960-968. doi: 10.1007/s00259-017-3669-5. Epub 2017 Mar 9. Eur J Nucl Med Mol Imaging. 2017. PMID: 28280856
68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer.
von Klot CJ, Merseburger AS, Böker A, Schmuck S, Ross TL, Bengel FM, Kuczyk MA, Henkenberens C, Christiansen H, Wester HJ, Solass W, Lafos M, Derlin T. von Klot CJ, et al. Among authors: henkenberens c. Nucl Med Mol Imaging. 2017 Dec;51(4):314-322. doi: 10.1007/s13139-017-0476-7. Epub 2017 Mar 7. Nucl Med Mol Imaging. 2017. PMID: 29242725 Free PMC article.
PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.
Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM. Derlin T, et al. Among authors: henkenberens c. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):913-922. doi: 10.1007/s00259-017-3924-9. Epub 2018 Jan 7. Eur J Nucl Med Mol Imaging. 2018. PMID: 29308527
Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.
Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, Kiefer S, Rischke HC, Reichel K, Schmidt-Hegemann NS, Ilhan H, Chirindel AF, Nicolas G, Henkenberens C, Derlin T, Bronsert P, Mavroidis P, Chen RC, Meyer PT, Ruf J, Grosu AL. Zamboglou C, et al. Among authors: henkenberens c. Radiother Oncol. 2019 Dec;141:208-213. doi: 10.1016/j.radonc.2019.07.002. Epub 2019 Aug 17. Radiother Oncol. 2019. PMID: 31431386
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Christiansen H, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M. Kroeze SGC, et al. Among authors: henkenberens c. Eur Urol Focus. 2021 Mar;7(2):309-316. doi: 10.1016/j.euf.2019.08.012. Epub 2019 Sep 5. Eur Urol Focus. 2021. PMID: 31495759
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study.
Schmidt-Hegemann NS, Kroeze SGC, Henkenberens C, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Müller AC, Grosu AL, Combs SE, Christiansen H, Guckenberger M, Belka C. Schmidt-Hegemann NS, et al. Among authors: henkenberens c. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1852-1863. doi: 10.1007/s00259-020-04708-y. Epub 2020 Jan 30. Eur J Nucl Med Mol Imaging. 2020. PMID: 32002591
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy.
Vogel MME, Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Mix M, la Fougère C, Eiber M, Christiansen H, Belka C, Grosu AL, Müller AC, Guckenberger M, Combs SE. Vogel MME, et al. Among authors: henkenberens c. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2328-2338. doi: 10.1007/s00259-020-04760-8. Epub 2020 Mar 16. Eur J Nucl Med Mol Imaging. 2020. PMID: 32179961 Free PMC article.
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK, Kroeze SGC, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M, Christiansen H, Henkenberens C. Oehus AK, et al. Among authors: henkenberens c. BMC Cancer. 2020 Apr 29;20(1):362. doi: 10.1186/s12885-020-06883-5. BMC Cancer. 2020. PMID: 32349700 Free PMC article.
74 results